Episurf Medical initiated a prospective investigator-initiated European multicentre study with five years of follow-up on 25 Episealer® Talus patients. Ppatients in the study will be followed up over five years with the subjective outcome measures VAS pain score, Foot and Ankle Outcome Score and EQ-5D-5L which is an instrument used for evaluation of life quality.
Episealer Talus is Episurf Medical’s CE Marked joint implant intended for treatment of osteochondral ankle lesions.
“I am pleased with this study design and it is important to gather clinical data for this promising technology”, says Prof. Niek van Dijk.
“Robust clinical evidence is very important for us at Episurf and we are happy that a user group lead by Prof. Niek van Dijk decided to take this initiative,” said Pål Ryfors, CEO Episurf Medical.
Episurf Medical initiated a prospective investigator-initiated European multicentre study with five years of follow-up on 25 Episealer® Talus patients. Ppatients in the study will be followed up over five years with the subjective outcome measures VAS pain score, Foot and Ankle Outcome Score and EQ-5D-5L which is an instrument used for evaluation...
Episurf Medical initiated a prospective investigator-initiated European multicentre study with five years of follow-up on 25 Episealer® Talus patients. Ppatients in the study will be followed up over five years with the subjective outcome measures VAS pain score, Foot and Ankle Outcome Score and EQ-5D-5L which is an instrument used for evaluation of life quality.
Episealer Talus is Episurf Medical’s CE Marked joint implant intended for treatment of osteochondral ankle lesions.
“I am pleased with this study design and it is important to gather clinical data for this promising technology”, says Prof. Niek van Dijk.
“Robust clinical evidence is very important for us at Episurf and we are happy that a user group lead by Prof. Niek van Dijk decided to take this initiative,” said Pål Ryfors, CEO Episurf Medical.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
